GlobeNewswire by notified

Copenhagen Infrastructure Partners and Uniper enter hydrogen partnership

Share

Copenhagen Infrastructure Partners (CIP), through its Energy Transition Fund, and Uniper have signed a memorandum of understanding to strengthen collaboration on bringing green hydrogen from CIP’s HØST PtX Esbjerg project to Germany.

COPENHAGEN, Denmark, May 02, 2024 (GLOBE NEWSWIRE) -- The partnership between CIP and Uniper, a global energy merchant and one of the world’s largest power producers, will drive collaboration on the production, transport, and marketing of green hydrogen from the HØST PtX Esbjerg project, located on the Danish Westcoast, to Germany.

It is expected that HØST as ultimo 2028, will be connected to the German hydrogen backbone via a new hydrogen pipeline to be developed from Denmark to Germany by the Danish transmission system operator Energinet in cooperation with Gasunie Deutschland Transport Services. This will enable access to the consumption sites in Germany and help bring competitively priced green hydrogen to the German market.

In partnership, CIP and Uniper will develop a model to bring up to 140,000 tons of green hydrogen annually to customers in Germany. Uniper intends to include the green hydrogen from HØST into its green gas portfolio and supply the industry’s needs with varying flexibility profiles and with different contract lengths.

Holger Kreetz, COO at Uniper: “We see great potential in this collaboration. HØST fits our strategic target of achieving at least 1 GW installed electrolyser capacity by 2030 and our other electrolyser developments in Germany such as Green Wilhelmshaven. Uniper’s diversified hydrogen portfolio consists of various supply sources to guarantee competitive and secure supplies in line with customer needs.”

Karsten Plauborg, partner at CIP commented: “This is an important step for CIP and the HØST PtX Esbjerg project. With the vast renewable energy potential from the North Sea as well as the planned hydrogen pipeline connecting Denmark to Germany, we are excited to take the next step in bringing the green hydrogen from the HØST project to German customers. While CIP has a significant portfolio of power-to-gas projects, Uniper’s strong position with German energy customers is a key enabler in establishing this new market.”

About Copenhagen Infrastructure Partners (CIP)
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focus on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.

CIP manages 12 funds and has to date raised approximately EUR 28 billion for investments in energy and associated infrastructure from more than 160 international institutional investors. CIP has approximately 500 employees and 12 offices around the world.

About HØST PtX Esbjerg
Part of CIP’s Energy Transition Fund I, the HØST PtX Esbjerg project is a leading, Danish Power-to-X project under development, deploying large-scale industrial use of electrolysis technology on gigawatt level to produce green hydrogen. Powered entirely by renewables, HØST PtX Esbjerg will produce up to 140,000 tonnes of green hydrogen per annum for use in the chemicals industry, predominantly expected in the German market.

About Uniper
Düsseldorf-based Uniper is an international energy company with activities in more than 40 countries. The company and its roughly 7,000 employees make an important contribution to supply security in Europe, particularly in its core markets of Germany, the United Kingdom, Sweden, and the Netherlands.

Uniper’s operations encompass power generation in Europe, global energy trading, and a broad gas portfolio. Uniper procures gas—including liquefied natural gas (LNG)—and other energy sources on global markets. The company owns and operates gas storage facilities with a total capacity of more than 7 billion cubic meters.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Constellation Brands to Present at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202416.5.2024 22:30:20 CEST | Press release

VICTOR, N.Y., May 16, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 2:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non-GAAP financial measures, will also be available

DBV Technologies Announces Results of its 2024 Combined General Meeting16.5.2024 22:30:00 CEST | Press release

Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company’s website: https://dbv-technologies.com/events/2024-annual-general-meeting/. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with sign

Clean Motion AB delårsredogörelse för januari-mars 202416.5.2024 22:10:00 CEST | Pressemelding

Elfordonstillverkaren Clean Motion AB presenterar sin delårsrapport för januari-mars 2024. Bolaget redovisar en försäljning på 38 (45) TSEK och ett rörelseresultat exklusive avskrivningar (EBITDA) på -2 949 (-1 825) TSEK. Bolaget meddelar även att ett licensavtal är tecknat för tillverkning av Zbee i Indien samt att deras nya produktionslokal för EVIG i Jonsered nu är godkänd. Sofia Haby, VD kommenterar; ”Vi har jobbat intensivt under kvartalet med både typgodkännande-processen och flytt till nya lokaler. Kvartalet har präglats av de förseningar som vi drabbats av med vårt typgodkännande, vilket förhindrat försäljning i Europa. Jag kan nu med glädje meddela att det mest kritiska testet blev godkänt igår kväll! Under de senaste månaderna har vi jobbat med att färdigställa vår nya produktionslokal i Jonsered. Jag är övertygad om att vi genom att samla alla resurser under ett tak, kommer att åstadkomma stora effektivitetsförbättringar. Teamet har arbetat dedikerat med att säkerställa en s

Galapagos creates new subscription right plans16.5.2024 22:01:00 CEST | Press release

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2024 ROW”, primarily intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 1,614,000 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH16.5.2024 22:00:00 CEST | Press release

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered.The DMC review confirms the good safety profile of lanifibranor. Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepa

HiddenA line styled icon from Orion Icon Library.Eye